Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Fatty Liver Treatment Market Size, Value And Growth Trajectory Through 2030
The fatty liver treatment market has experienced robust growth in recent years. It is projected to expand from $25.05 billion in 2025 to $26.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. This historical growth can be attributed to several factors including an increase in obesity rates, rising diabetes prevalence, improvements in liver diagnostic tools, growing awareness of liver health, and the expansion of hepatology clinics.
The fatty liver treatment market is projected for substantial expansion in the coming years, reaching a valuation of $35.67 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.5%. This anticipated growth during the forecast period is attributable to several factors, including the creation of new NAFLD medications, the greater adoption of non-invasive diagnostic methods, the expansion of preventive healthcare initiatives, the wider availability of tele-hepatology services, and increased funding for liver disease research. Key trends expected over the forecast horizon encompass the increasing incidence of non-alcoholic fatty liver disease, a heightened emphasis on lifestyle-oriented treatment strategies, the broader application of targeted drug therapies, an increase in early liver disease screening efforts, and the incorporation of digital health solutions for disease tracking.
Get A Free Sample Report With In-Depth Market Insights:
Fatty Liver Treatment Market Development Factors: What’s Supporting Demand?
Rising alcohol consumption is anticipated to propel the expansion of the fatty liver treatment market in the future. This consumption refers to the intake of beverages that contain alcohol, which is a psychoactive substance known for its depressant effects on the central nervous system. Alcohol consumption can exacerbate fatty liver disease and potentially lead to more severe liver conditions, including alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. For instance, in November 2025, the OECD, a Paris-based intergovernmental organization, reported that in 2023, the average annual per capita alcohol consumption across its member countries stood at 8.5 liters of pure alcohol. Consequently, the increasing levels of alcohol consumption are a primary driver for the growth of the fatty liver treatment market.
Fatty Liver Treatment Market Segment Landscape And Growth Outlook
The fatty liver treatment market covered in this report is segmented –
1) By Treatment Type: Anti-Viral Drugs, Chemotherapy Drugs, Targeted Therapy, Anti-Fibrotic Drugs
2) By Disease Type: Hepatitis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Other Diseases
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users
Subsegments:
1) By Anti-Viral Drugs: Direct-Acting Antivirals (DAAs), Nucleos(t)ide Analogs
2) By Chemotherapy Drugs: Conventional Chemotherapy Agents, Novel Chemotherapeutics Under Investigation
3) By Targeted Therapy: Small Molecule Inhibitors, Monoclonal Antibodies
4) By Anti-Fibrotic Drugs: PPAR Agonists, FXR Agonists, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Other Insulin Sensitizers
Fatty Liver Treatment Market Trends Powering Strategic Industry Growth
Prominent companies operating in the fatty liver treatment market are dedicated to devising novel solutions, including next-generation metabolic-modulating biologics, to fulfill the escalating demand for effective treatments that target the core mechanisms of NAFLD and NASH. These biologic therapies engage with crucial metabolic and inflammatory pathways, presenting a more focused and disease-modifying approach compared to traditional lifestyle-based interventions, which offer restricted therapeutic impact for advanced disease. For instance, in March 2023, Akero Therapeutics, a US-based biotechnology company, released positive Phase II reports for efruxifermin, a treatment intended for non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It functions as a differentiated Fc-FGF21 fusion protein, mimicking the biological activity of fibroblast growth factor 21 (FGF21), which regulates a multitude of metabolic pathways and cellular processes.
Fatty Liver Treatment Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the fatty liver treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Intercept Pharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Genfit, Conatus Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Cardax Inc., Eisai Co. Ltd., Alnylam Pharmaceuticals Inc.
View The Full Fatty Liver Treatment Market Report:
Fatty Liver Treatment Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the fatty liver treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fatty liver treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
